Observational studyCancer2021
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC).
Observational study in Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 60 citations in OpenAlex.
- Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial.The Lancet. Oncology · 2021Trial
- Effect of First-Line Combination Systemic Therapy on Favorable-Risk Clear Cell Renal Cell Carcinoma: A Retrospective Study.Biomedicines · 2026Article
- First-Line Treatment Strategies in IMDC Favourable-Risk Metastatic Clear Cell Renal Cell Carcinoma.Oncology research · 2026Review
- The correlation between clinical and pathological features of renal cancer patients with survival after surgical intervention.Caspian journal of internal medicine · 2026Article
- Review
- Development of a prognostic risk model for clear cell renal cell carcinoma by systematic evaluation of DNA methylation markers: an update after ISUP/WHO 2022 classification.The journal of pathology. Clinical research · 2025Article
- 2024 CUA-KCRNC Expert Report: Management of non-clear cell renal cell carcinoma.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024Article
- The Treatment of Metastatic Renal Cell Carcinoma.Deutsches Arzteblatt international · 2024Review
- Contemporary Management of Renal Cell Carcinoma: A Review for General Practitioners in Oncology.Current oncology (Toronto, Ont.) · 2024Review
- Design and Rationale of the Outcomes Database to Prospectively Assess the Changing Therapy Landscape in Renal Cell Carcinoma Registry: A Multi-institutional, Prospective Study of Patients with Metastatic Renal Cell Carcinoma.European urology open science · 2024Article
- The impact of the COVID-19 pandemic on renal cancer care.World journal of urology · 2024Article
- Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update.Journal of cancer research and clinical oncology · 2024Review
- Morbidity and Outcomes of Primary Tumor Management in Patients with Widely Metastatic Well-Differentiated Small Bowel Neuroendocrine Tumors.Annals of surgical oncology · 2024Article
- Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review.Future oncology (London, England) · 2024Review
- Active Surveillance in Metastatic Renal Cell Carcinoma.Journal of kidney cancer and VHL · 2024Review
- The Diagnosis and Treatment Approach for Oligo-Recurrent and Oligo-Progressive Renal Cell Carcinoma.Cancers · 2023Review
- High Prognostic Value ofDiagnostics (Basel, Switzerland) · 2023Article
- ExPert ConsEnsus on the management of Advanced clear-cell RenaL celL carcinoma: INDIAn Perspective (PEARL-INDIA).BMC cancer · 2023Article
- Prognostic Factors for Survival in Patients Undergoing Surveillance After Cytoreductive Nephrectomy.The Journal of urology · 2023Article
- Beyond the Knife in Renal Cell Carcinoma: A Systematic Review-To Ablate or Not to Ablate?Cancers · 2023Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
24 authors at 19 institutions in 1 country.
Funding
Abstract
backgroundSystemic therapy (ST) can be deferred in patients who have metastatic renal cell carcinoma (mRCC) and slow-growing metastases. Currently, this subset of patients managed with active surveillance (AS) is not well described in the literature.
methodsThis was a prospective observational study of patients with mRCC across 46 US community and academic centers. The objective was to describe baseline characteristics and demographics of patients with mRCC initially managed by AS, reasons for AS, and patient outcomes. Descriptive statistics were used to characterize demographics, baseline characteristics, and patient-related outcomes. Wilcoxon 2-sample rank-sum tests and χ
resultsOf 504 patients, mRCC was initially managed by AS (n = 143) or ST (n = 305); 56 patients were excluded from the analysis. Disease was present in 69% of patients who received AS, whereas the remaining 31% had no evidence of disease. At data cutoff, 72 of 143 patients (50%) in the AS cohort had not received ST. The median overall survival was not reached (95% CI, 122 months to not estimable) in patients who received AS versus 30 months (95% CI, 25-44 months) in those who received ST. Quality of life at baseline was significantly better in patients who were managed with AS versus ST.
conclusionsAS occurs frequently (32%) in real-world clinical practice and appears to be a safe and appropriate alternative to immediate ST in selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.